UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) (State of other jurisd ...

OptiNose Inc. (NASDAQ:OPTN) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Operations Ramy Mahmoud - CEO Paul Spence - CCO Conference Call Participants Operator Hello. Good day everyone and thank you for standing by. Welcome to the OptiNose Second Quarter 2023 Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Plea ...

| --- | --- | --- | |-------|-------|----------------------------------------------| | | | | | | | FDA accepted for review our supplemental new | optinose® Q2 2023 Performance XHANCE New Prescriptions increased 3%, Total Prescriptions increased 3% and HCPs who had a prescription filled by their patients increased 4% from Q2 2022 to Q2 2023 8 XHANCE Prescriptions – Second Quarter 2023 30.1 30.9 Q2 '22 Q2 '23 (in thousands) XHANCE New Prescriptions 87.7 90.7 Q2 '22 Q2 '23 XHANCE Total Prescriptions (in thousa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

OptiNose Inc. (NASDAQ:OPTN) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President, Investor Relatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State of other jur ...

OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Conference Call March 7, 2023 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Joe Scodari - Chairman Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies David Amsellem - Piper Sandler Operator Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 E ...

OptiNose, Inc. (NASDAQ:OPTN) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Peter Miller - CEO Ramy Mahmoud - President and COO Conference Call Participants Glenn Santangelo - Jefferies Isaac Somekh - Piper Sandler Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Brandon Folkes - Cantor Jonathan Neely [Starts Abruptly] Third quarter 2022 performance and our plans for the remainder of the year. I'm joined today by our CEO ...

OptiNose, Inc. (NASDAQ:OPTN) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Operator Good day, and thank you for standing by. Welcome to the OptiNose's Second Quarter 2022 Earnings Call. [Operator Instructions] Please be advised that today's conference is being ...